Makers Laboratories Ltd Downgraded to Sell Amid Valuation and Financial Concerns

Valuation Shift from Attractive to Fair

The most significant trigger for the downgrade is the change in Makers Laboratories’ valuation grade. Previously rated as attractive, the valuation has now been reassessed as fair. The company’s price-to-earnings (PE) ratio stands at a relatively high 38.74, which, while lower than some peers, still indicates a premium valuation. For context, competitors such as Bliss GVS Pharma and Kwality Pharma are rated as very expensive with PE ratios of 42.93 and 41.45 respectively, but Makers Labs’ EV to EBITDA multiple of 5.77 is notably lower than many peers, suggesting some operational efficiency.

Other valuation metrics include a price-to-book value of 1.25 and an enterprise value to capital employed ratio of 1.27, both indicating a fair but not undervalued position. The PEG ratio remains at zero, reflecting no expected earnings growth, which further dampens valuation appeal. Dividend yield data is unavailable, which may also weigh on investor sentiment.

Financial Trend: Mixed Signals Amid Weak Long-Term Growth

While Makers Laboratories reported positive financial results for Q4 FY25-26, including record quarterly net sales of ₹35.75 crores and PBDIT of ₹5.27 crores, the longer-term financial trend remains a concern. The company has experienced a negative compound annual growth rate (CAGR) of -7.99% in operating profits over the past five years, signalling deteriorating profitability.

Return on equity (ROE) is particularly weak, with the latest figure at 3.22% and a five-year average of just 4.67%. This low profitability per unit of shareholder funds contrasts with the return on capital employed (ROCE) of 15.26%, which is relatively healthy but insufficient to offset concerns about overall earnings quality and growth sustainability.

Moreover, despite a strong debtors turnover ratio of 7.08 times in the half-year period, indicating efficient receivables management, the company’s profits have declined sharply by 71.7% over the past year. This disconnect between sales growth and profit erosion raises questions about margin pressures and cost management.

Quality Assessment: Weak Long-Term Fundamentals

The quality parameter remains a weak point for Makers Laboratories. Despite some operational efficiencies, the company’s long-term fundamental strength is undermined by its negative operating profit growth and low ROE. The average ROE of 4.67% over five years is significantly below industry standards, indicating limited value creation for shareholders.

Additionally, the company’s micro-cap status and relatively modest market capitalisation contribute to higher risk and lower liquidity, factors that weigh on the quality grade. Promoter holdings remain majority, which can be a double-edged sword, offering stability but also raising concerns about governance and minority shareholder influence.

Technicals: Recent Price Movements and Relative Performance

Technically, Makers Laboratories has shown mixed signals. The stock closed at ₹152.90 on 30 June 2026, up 3.80% on the day, with a high of ₹154.30 and a low of ₹146.15. Over the past week, the stock gained 3.45%, outperforming the Sensex which declined by 0.47%. However, over the past month, the stock fell 6.63% while the Sensex rose 2.61%, reflecting short-term volatility.

Year-to-date, Makers Laboratories has delivered a robust 29.41% return, significantly outperforming the Sensex’s negative 9.96% return. Over three years, the stock has appreciated 38.31%, again beating the benchmark’s 20.05%. Yet, over five years, the stock has underperformed with an 18.45% decline compared to the Sensex’s 46.01% gain, highlighting inconsistent performance over longer horizons.

These mixed technical signals, combined with valuation and fundamental concerns, have contributed to the downgrade to a Sell rating with a Mojo Score of 47.0, down from a previous Hold grade.

Comparative Industry Context

Within the Pharmaceuticals & Biotechnology sector, Makers Laboratories’ valuation metrics place it in a fair category, contrasting with many peers rated as very expensive or risky. For example, Bliss GVS Pharma and Hester Biosciences are considered very expensive with PE ratios above 35 and EV to EBITDA multiples exceeding 24, while Fredun Pharma is rated attractive despite a higher PE ratio of 40.16.

This relative valuation positioning suggests that while Makers Laboratories is not the most expensive stock in its peer group, its lack of earnings growth and weak profitability metrics justify a cautious stance. Investors may prefer companies with stronger financial trends and higher quality scores within the sector.

Outlook and Investor Considerations

Investors should weigh the recent positive quarterly sales and operational metrics against the longer-term challenges faced by Makers Laboratories. The downgrade to Sell reflects concerns over valuation fairness, weak long-term profit growth, and low returns on equity, which collectively undermine the stock’s investment appeal despite some short-term momentum.

Given the micro-cap status and the stock’s mixed technical performance, risk-averse investors may consider reducing exposure or exploring alternative opportunities within the sector that offer stronger fundamentals and more attractive valuations.

Summary of Ratings and Scores

Makers Laboratories Ltd currently holds a Mojo Score of 47.0 with a Sell grade, downgraded from Hold on 29 June 2026. The valuation grade shifted from attractive to fair, reflecting a reassessment of price multiples and growth prospects. Quality remains weak due to low ROE and negative operating profit trends, while financial trends show mixed signals with recent quarterly strength but long-term deterioration. Technicals indicate short-term momentum but inconsistent longer-term performance.

Overall, the downgrade signals a cautious outlook for Makers Laboratories, urging investors to carefully analyse the company’s fundamentals and valuation before committing capital.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →